Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations

被引：13

作者：

van Dam, Koos P. J. ^{[1
]}

Wieske, Luuk ^{[1
,2
]}

Stalman, Eileen W. ^{[1
]}

Kummer, Laura Y. L. ^{[1
,3
]}

Roosen, Jesse ^{[1
]}

van Kempen, Zoe L. E. ^{[4
]}

Killestein, Joep ^{[4
]}

Volkers, Adriaan G. ^{[5
]}

Boekel, Laura ^{[6
]}

Wolbink, Gerrit J. ^{[6
]}

van der Kooi, Anneke J. ^{[1
]}

Raaphorst, Joost ^{[1
]}

Lowenberg, Mark ^{[5
]}

Takkenberg, R. Bart ^{[5
]}

D'Haens, Geert R. A. M. ^{[5
]}

Spuls, Phyllis I. ^{[7
]}

Bekkenk, Marcel W. ^{[7
]}

Musters, Annelie H. ^{[7
]}

Post, Nicoline F. ^{[7
]}

Bosma, Angela L. ^{[7
]}

Hilhorst, Marc L. ^{[8
]}

Vegting, Yosta ^{[8
]}

Bemelman, Frederike J. ^{[8
]}

Voskuyl, Alexandre E. ^{[9
]}

Broens, Bo ^{[9
]}

Sanchez, Agner Parra ^{[9
,10
]}

van Els, Cecile A. C. M. ^{[11
,12
]}

de Wit, Jelle ^{[11
]}

Rutgers, Abraham ^{[13
]}

de Leeuw, Karina ^{[13
]}

Horvath, Barbara ^{[14
]}

Verschuuren, Jan J. G. M. ^{[15
]}

Ruiter, Annabel M. ^{[15
]}

van Ouwerkerk, Lotte ^{[16
]}

van der Woude, Diane ^{[16
]}

Allaart, Renee C. F. ^{[16
]}

Teng, Y. K. Onno ^{[17
]}

van Paassen, Pieter ^{[18
]}

Busch, Matthias H. ^{[18
]}

Jallah, Papay B. P. ^{[18
]}

Brusse, Esther ^{[19
]}

van Doorn, Pieter A. ^{[19
]}

Baars, Adaja E. ^{[19
]}

Hijnen, Dirk Jan ^{[20
]}

Schreurs, Corine R. G. ^{[20
]}

van der Pol, W. Ludo ^{[21
]}

Goedee, H. Stephan ^{[21
]}

Steenhuis, Maurice ^{[3
]}

Keijzer, Sofie ^{[3
]}

Keijser, Jim B. D. ^{[3
]}

机构：

[1] Univ Amsterdam, Dept Neurol & Neurophysiol, Amsterdam Neurosci, Amsterdam UMC, Amsterdam, Netherlands

[2] St Antonius Hosp, Dept Clin Neurophysiol, Nieuwegein, Netherlands

[3] Amsterdam UMC, Dept Immunopathol, Sanquin Res & Landsteiner Lab, Amsterdam, Netherlands

[4] Vrije Univ Amsterdam, Dept Neurol, Amsterdam UMC, Med Ctr, Amsterdam, Netherlands

[5] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam UMC, Amsterdam, Netherlands

[6] Reade, Amsterdam Rheumatol & Immunol Ctr, Dept Rheumatol, Amsterdam, Netherlands

[7] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, Amsterdam UMC, Amsterdam, Netherlands

[8] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Sect Nephrol, Amsterdam, Netherlands

[9] Vrije Univ Amsterdam, Amsterdam Rheumatol & Immunol Ctr, Dept Rheumatol & Clin Immunol, Med Ctr, Amsterdam, Netherlands

[10] Univ Amsterdam, Amsterdam Rheumatol & Immunol Ctr, Dept Rheumatol & Clin Immunol, Amsterdam UMC, Amsterdam, Netherlands

[11] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands

[12] Univ Utrecht, Fac Vet Med, Utrecht, Netherlands

[13] Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, Groningen, Netherlands

[14] Univ Groningen, Univ Med Ctr Groningen, Ctr Blistering Dis, Dept Dermatol, Groningen, Netherlands

[15] Leiden Univ, Dept Neurol, Med Ctr, Leiden, Netherlands

[16] Leiden Univ, Dept Rheumatol, Med Ctr, Leiden, Netherlands

[17] Leiden Univ, Ctr Expertise Lupus Vasculitis & Complement Media, Dept Internal Med Nephrol Sect, Med Ctr, Leiden, Netherlands

[18] Maastricht Univ, Dept Nephrol & Clin Immunol, Med Ctr, Maastricht, Netherlands

[19] Univ Med Ctr, Dept Neurol, Erasmus MC, Rotterdam, Netherlands

[20] Univ Med Ctr, Dept Dermatol, Erasmus MC, Rotterdam, Netherlands

[21] UMC Utrecht, Dept Neurol & Neurosurg, Brain Ctr, Utrecht, Netherlands

[22] Univ Amsterdam, Swammerdam Inst Life Sci, Amsterdam, Netherlands

[23] Univ Amsterdam, Dept Pediat Immunol Rheumatol & Infect Dis, Amsterdam UMC, AMC, Amsterdam, Netherlands

来源：

JOURNAL OF AUTOIMMUNITY | 2023年 / 135卷

关键词：

SARS-CoV-2; COVID-19; Vaccination; Autoimmune disease; Disease activity; Flare;

D O I：

10.1016/j.jaut.2022.102984

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

For patients with immune-mediated inflammatory diseases (IMIDs), concerns exist about increased disease ac-tivity after vaccination. We aimed to assess changes in disease activity after SARS-CoV-2 vaccination in patients with IMIDs, and determine risk factors for increased disease activity. In this substudy of a prospective obser-vational cohort study (Target-to-B!), we included patients with IMIDs who received a SARS-CoV-2 vaccine. Patients reported changes in disease activity on a five-point Likert scale every 60 days for up to twelve months after first vaccination. In case of self-reported increased activity, hospital records were screened whether the treating physician reported increased activity, and for potential intensification of immunosuppressive (ISP) treatment. Mixed models were used to study determinants for self-reported increased disease activity. In total, 2111 patients were included for analysis after primary immunization (mean age 49.7 years [SD 13.7], 1329/ 2111 (63.0%) female), from which 1266 patients for analysis after first additional vaccination. Increased disease activity at 60 days after start of primary immunization was reported by 223/2111 (10.6%). In 96/223 (43.0%) the increase was confirmed by the treating physician and in 36/223 (16.1%) ISP treatment was intensified. Increased disease activity at seven to 60 days after additional vaccination, was reported by 139/1266 (11.0%). Vaccinations were not temporally associated with self-reported increased disease activity. Conversely, increased disease activity before first vaccination, neuromuscular disease, and multiple sclerosis were associated. Alto-gether, self-reported increased disease activity after vaccination against SARS-CoV-2 was recorded in a minority of patients and was generally mild. Moreover, multivariate analyses suggest that disease related factors, but not vaccinations are the major determinants for self-reported increased disease activity.

引用

页数：9

共 50 条

[41] Sleep Disturbance and SARS-CoV-2 Vaccinations in Patients With Chronic Inflammatory Disease
Pawar, Niti
Taylor, Kimberly E.
Yang, Monica
Deepak, Parakkal
Kim, Wooseob
Paley, Michael A.
Matloubian, Mehrdad
Carvidi, Alex
Ciorba, Matthew A.
Demissie, Emanuel
El-Qunni, Alia
Huang, Katherine
Kinnett, Baylee
McMorrow, Lily E.
Paez, Diana
Poole, Mackenzie
Rose, Abigail
Schriefer, Rebecca E.
Kim, Alfred H. J.
Nakamura, Mary
Katz, Patricia
Gensler, Lianne S.
ARTHRITIS CARE & RESEARCH, 2023, : 1849 - 1856
[42] IMMUNE RESPONSES TO MRNA VACCINES AGAINST SARS-COV2 IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
Sieiro Santos, C.
Moriano, C.
Diez Alvarez, E.
Calleja Antolin, S.
Gonzalez Fernandez, I.
Alvarez Castro, C.
Ruiz de Morales, J. M. Garcia
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 923 - 923
[43] Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment
Raussi, Eve-Kai
Eisen, Maigi
Palk, Kullike
Kutt, Marge
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 474 - 475
[44] IMMUNE RESPONSES TO MRNA VACCINES AGAINST SARS-COV2 IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
Sieiro Santos, Cristiana
Calleja Antolin, Sara
Moriano Morales, Clara
Alvarez Castro, Carolina
Diez Alvarez, Elvira
Garcia Ruiz de Morales, Jose Maria
RHEUMATOLOGY, 2023, 62
[45] Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease
Al-Janabi, A.
Littlewood, Z.
Griffiths, C. E. M.
Hunter, H. J. A.
Chinoy, H.
Moriarty, C.
Yiu, Z. Z. N.
Warren, R. B.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : 646 - 648
[46] Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
Jyssum, Ingrid
Tveter, Anne Therese
Sexton, Joe
Christensen, Ingrid Egeland
Mjaaland, Siri
Warren, David
Kvien, Tore K.
Bjorlykke, Kristin Hammersboen
Kro, Grete Birkeland
Jahnsen, Jorgen
Munthe, Ludvig A.
Haavardsholm, Espen
Grodeland, Gunnveig
Provan, Sella Aarrestad
Jorgensen, Kristin Kaasen
Goll, Guro
Syversen, Silje Watterdal
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1575 - 1577
[47] Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study
Jorgensen, K. K.
Syversen, S. W.
Jyssum, I.
Tveter, A. T.
Tran, T. T.
Sexton, J.
Provan, S. A.
Mjaaland, S.
Warren, D. J.
Kvien, T. K.
Grodeland, G.
Nissen-Meyer, L. S.
Ricanek, P.
Chopra, A.
Andersson, A. M.
Kro, G. B.
Jahnsen, J.
Munthe, L. A.
Haavardsholm, E. A.
Vaage, J. T.
Lund-Johansen, F.
Goll, G. L.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I537 - I538
[48] The Immunogenicity and Safety of Three Types of SARS-CoV-2 Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Longitudinal Cohort Study
Tien, Ni
Chang, Yu-Chang
Chen, Po-Ku
Lin, Hui-Ju
Chang, Shih-Hsin
Lan, Joung-Liang
Hsueh, Po-Ren
Chang, Ching-Kun
Chen, Der-Yuan
BIOMEDICINES, 2022, 10 (04)
[49] IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
Reddy, Kavya
Grody, Wayne W.
Sarkissian, Ariella
Getzug, Terri
GASTROENTEROLOGY, 2022, 162 (07) : S287 - S287
[50] Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study
Jorgensen, K. K.
Syversen, S. W.
Jyssum, I.
Tveter, A. T.
Tran, T. T.
Sexton, J.
Provan, S. A.
Mjaaland, S.
Warren, D. J.
Kvien, T. K.
Grodeland, G.
Nissen-Meyer, L. S.
Ricanek, P.
Chopra, A.
Andersson, A. M.
Kro, G. B.
Jahnsen, J.
Munthe, L. A.
Haavardsholm, E. A.
Vaage, J. T.
Lund-Johansen, F.
Goll, G. L.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I537 - I538

← 1 2 3 4 5 →